高剂量与标准剂量维生素D3补充对晚期或转移性结直肠癌患者无进展生存期的影响:SUNSHINE随机临床试验
这项双盲2期随机临床试验纳入139例晚期或转移性结直肠癌患者,在美国11个中心比较标准化疗联合高剂量或标准剂量维生素D3的疗效。高剂量组中位无进展生存期为13.0个月,标准剂量组为11.0个月,log-rank检验P=0.07未达统计学显著,但多变量风险比为0.64(单侧95%CI 0-0.90;P=0.02)。两组肿瘤客观缓解率和总生存期无显著差异。
要点
- 高剂量维生素D3组中位PFS为13.0个月,标准剂量组为11.0个月,log-rank P=0.07未达统计学显著。
- 多变量分析中高剂量组疾病进展或死亡风险比为0.64(单侧95%CI 0-0.90;P=0.02)。
- 两组肿瘤客观缓解率和总生存期无显著差异。
核心结论
- 在转移性结直肠癌患者中,标准化疗联合高剂量维生素D3与标准剂量相比,中位无进展生存期差异未达统计学显著,但支持性风险比显著改善。
- 这些发现需要在更大规模的多中心随机临床试验中进一步评估。
研究设计与样本
- 双盲2期随机临床试验,纳入139例晚期或转移性结直肠癌患者。
- 2012年3月至2016年11月在美国11个学术和社区癌症中心开展,数据库锁定时间为2018年9月。
- 干预为每2周mFOLFOX6联合贝伐珠单抗化疗,并每日给予高剂量维生素D3(n=69)或标准剂量维生素D3(n=70),直至疾病进展、不可耐受毒性或撤回知情同意。
- 主要终点为无进展生存期,采用log-rank检验和Cox比例风险模型分析,检验为单侧。
- 患者平均年龄56岁,女性60例(43%),中位随访22.9个月。
主要发现
- 高剂量维生素D3组中位无进展生存期为13.0个月(95%CI 10.1-14.7;49例PFS事件),标准剂量组为11.0个月(95%CI 9.5-14.0;62例PFS事件),log-rank P=0.07。
- 多变量分析中,高剂量组与标准剂量组相比,疾病进展或死亡的风险比为0.64(单侧95%CI 0-0.90;P=0.02)。
- 肿瘤客观缓解率高剂量组为58%,标准剂量组为63%,差异为-5%(95%CI -20%至100%),P=0.27。
- 总生存期中位值高剂量组为24.3个月,标准剂量组为24.3个月,log-rank P=0.43。
- 血浆25(OH)D水平:基线高剂量组16.1 ng/mL vs 标准剂量组18.7 ng/mL(差异-2.6 ng/mL,95%CI -6.6至1.4,P=0.30);第一次再分期时32.0 ng/mL vs 18.7 ng/mL(差异12.8 ng/mL,95%CI 9.0-16.6,P<0.001);第二次再分期时35.2 ng/mL vs 18.5 ng/mL(差异16.7 ng/mL,95%CI 10.9-22.5,P<0.001);治疗终止时34.8 ng/mL vs 18.7 ng/mL(差异16.2 ng/mL,95%CI 9.9-22.4,P<0.001)。
关键数值与推荐
- 高剂量维生素D3组3级及以上不良事件中,中性粒细胞减少24例(35%),高血压9例(13%)。
- 标准剂量维生素D3组3级及以上不良事件中,中性粒细胞减少21例(31%),高血压11例(16%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现需要在更大规模的多中心随机临床试验中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In observational studies, higher plasma 25-hydroxyvitamin D (25[OH]D) levels have been associated with improved survival in metastatic colorectal cancer (CRC). OBJECTIVE: To determine if high-dose vitamin D3 added to standard chemotherapy improves outcomes in patients with metastatic CRC. DESIGN, SETTING, AND PARTICIPANTS: Double-blind phase 2 randomized clinical trial of 139 patients with advanced or metastatic CRC conducted at 11 US academic and community cancer centers from March 2012 through November 2016 (database lock: September 2018). INTERVENTIONS: mFOLFOX6 plus bevacizumab chemotherapy every 2 weeks and either high-dose vitamin D3 (n = 69) or standard-dose vitamin D3 (n = 70) daily until disease progression, intolerable toxicity, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) assessed by the log-rank test and a supportive Cox proportional hazards model. Testing was 1-sided. Secondary end points included tumor objective response rate (ORR), overall survival (OS), and change in plasma 25(OH)D level. RESULTS: Among 139 patients (mean age, 56 years; 60 [43%] women) who completed or discontinued chemotherapy and vitamin D3 (median follow-up, 22.9 months), the median PFS for high-dose vitamin D3 was 13.0 months (95% CI, 10.1 to 14.7; 49 PFS events) vs 11.0 months (95% CI, 9.5 to 14.0; 62 PFS events) for standard-dose vitamin D3 (log-rank P = .07); multivariable hazard ratio for PFS or death was 0.64 (1-sided 95% CI, 0 to 0.90; P = .02). There were no significant differences between high-dose and standard-dose vitamin D3 for tumor ORR (58% vs 63%, respectively; difference, -5% [95% CI, -20% to 100%], P = .27) or OS (median, 24.3 months vs 24.3 months; log-rank P = .43). The median 25(OH)D level at baseline for high-dose vitamin D3 was 16.1 ng/mL vs 18.7 ng/mL for standard-dose vitamin D3 (difference, -2.6 ng/mL [95% CI, -6.6 to 1.4], P = .30); at first restaging, 32.0 ng/mL vs 18.7 ng/mL (difference, 12.8 ng/mL [95% CI, 9.0 to 16.6], P < .001); at second restaging, 35.2 ng/mL vs 18.5 ng/mL (difference, 16.7 ng/mL [95% CI, 10.9 to 22.5], P < .001); and at treatment discontinuation, 34.8 ng/mL vs 18.7 ng/mL (difference, 16.2 ng/mL [95% CI, 9.9 to 22.4], P < .001). The most common grade 3 and higher adverse events for chemotherapy plus high-dose vs standard-dose vitamin D3 were neutropenia (n = 24 [35%] vs n = 21 [31%], respectively) and hypertension (n = 9 [13%] vs n = 11 [16%]). CONCLUSIONS AND RELEVANCE: Among patients with metastatic CRC, addition of high-dose vitamin D3, vs standard-dose vitamin D3, to standard chemotherapy resulted in a difference in median PFS that was not statistically significant, but with a significantly improved supportive hazard ratio. These findings warrant further evaluation in a larger multicenter randomized clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01516216.
引用
- Ng K, Nimeiri HS, McCleary NJ, et al. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019. PMID: 30964527. doi:10.1001/jama.2019.2402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。